Primary malignant tumors of the adrenal glands
Madson Q. Almeida,”,"",* Joao Evangelista Bezerra-Neto,” Berenice B. Mendonça,’ Ana Claudia Latronico,’ Maria Candida B.V. Fragoso1, !!
‘Unidade de Suprarrenal, Laboratorio de Hormonios e Genetica Molecular LIM/42, Servico de Endocrinologia e Metabologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR. ” Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Almeida MQ, Bezerra-Neto JE, Mendonça BB, Latronico AC, Fragoso MC. Primary malignant tumors of the adrenal glands. Clinics. 2018;73(suppl 1):e756s *Corresponding author. E-mail: madsonalmeida@usp.br / madson.a@hc.fm.usp.br
Malignancy must be considered in the management of adrenal lesions, including those incidentally identified on imaging studies. Adrenocortical carcinomas (ACCs) are rare tumors with an estimated annual incidence of 0.7-2 cases per year and a worldwide prevalence of 4-12 cases per million/year. However, a much higher incidence of these tumors (> 15 times) has been demonstrated in south and southeastern Brazil. Most ACCs cause hypersecretion of steroids including glucocorticoids and androgens. ACC patients have a very poor prognosis with a 5-year overall survival (OS) below 30% in most series. Pheochromocytoma or paraganglioma (PPGL) is a metabolically active tumor originating from the chromaffin cells of the adrenal medulla. The incidence of PPGL is 0.2 to 0.9 cases per 100,000 individuals per year. Pheochromocytomas are present in approximately 4-7% of patients with adrenal incidentalomas. Classically, PPGL manifests as paroxysmal attacks of the following 4 symptoms: headaches, diaphoresis, palpitations, and severe hypertensive episodes. The diagnosis of malignant PPGL relies on the presence of local invasion or metastasis. In this review, we present the clinical and biochemical characteristics and pathogenesis of malignant primary lesions that affect the cortex and medulla of human adrenal glands.
KEYWORDS: Adrenocortical Carcinoma; Pheochromocytoma; Paraganglioma; Treatment.
INTRODUCTION
Human adrenal glands can be affected by several malignant conditions. Indeed, malignancy must be consid- ered in the management of adrenal lesions, including those incidentally identified on imaging studies (adrenal inciden- talomas). Adrenal incidentalomas are identified in 1-4% of abdominal imaging studies, and the incidence of adrenal incidentaloma increases with age. In medical series, most adrenal incidentalomas are adenomas (80%), and only 8% are carcinomas. Therefore, the incidental discovery of an adrenal mass could be considered an opportunity to offer a curative approach for malignant lesions (1).
Adrenocortical carcinomas (ACCs) are rare tumors with an estimated annual incidence of 0.7-2 cases per year and a worldwide prevalence of 4-12 cases per million/year (2). However, a much higher incidence of adrenal tumors (>15 times) has been demonstrated in the pediatric population in south and southeastern Brazil, and these tumors are associated with a specific germline mutation in TP53 (3,4).
These malignant tumors can be diagnosed by endocrine signs of steroid excess, compression symptoms due to tumor growth or during evaluation of adrenal incidentalomas. The majority of adrenal tumors secrete excess cortisol, although this cortisol hypersecretion can be subclinical. ACC patients have a very poor prognosis with a 5-year overall survival (OS) below 30% in most series. Despite this unfavorable outcome, some patients are cured after surgical removal, and others have relatively slow metastatic progression. The recent discovery of genetic alterations underlying the pathogenesis of ACC have led to the identification of ACC subgroups with dismal prognoses (5).
Pheochromocytoma or paraganglioma (PPGL) is a meta- bolically active tumor originating from the chromaffin cells of the adrenal medulla. The incidence of PPGL is 0.2 to 0.9 cases per 100,000 individuals per year. Pheochromocytomas are present in approximately 4-7% of patients with adrenal incidentalomas. Classically, PPGL manifests as paroxysmal attacks of the following 4 symptoms: headaches, diaphoresis, palpitations, and severe hypertensive episodes. The diag- nosis of malignant PPGL relies on the presence of local invasion or metastasis. The most common sites of metastasis include bones, lymph nodes and the liver. In this review, we present the clinical and biochemical characteristics and pathogenesis of malignant primary lesions that affect the cortex and medulla of human adrenal glands (6).
Adrenocortical carcinoma
ACC presents a bimodal distribution, with the first peak in children <5 years and the second (7) peak during the 4th and 5th decades of life and a slight predominance in women (2,8).
Copyright @ 2018 CLINICS - This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/ 4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on April 24, 2018. Accepted for publication on October 23, 2018
Commemorative Edition: 10 years of ICESP
DOI: 10.6061/clinics/2018/e756s
In the pediatric population, only 25 new cases are diagnosed each year in the USA. In south and southeastern Brazil, approximately 78% of children and 13% of adults with adrenal tumors harbor a specific germline mutation (p.R337H) of the p53 tumor suppressor (9,10). A founder effect has been demonstrated in the great majority of pedia- tric Brazilian patients with adrenocortical tumors caused by this p53 mutation (11).
Virilization syndrome is the most frequent presentation of adrenal tumors during childhood. Hypercortisolism can be associated with androgen overproduction, mainly of dehy- droepiandrosterone sulfate (DHEAS) and testosterone, lead- ing to gonadotropin-independent precocious puberty (3,12). In adults, cortisol hypersecretion is the most common hormone disorder. Adult ACC can also be associated with virilization alone or a mixed syndrome (virilization and Cushing’s syndrome). Estrogen and aldosterone overproduc- tion are highly uncommon (2). Although uncommon, patients with advanced disease can present with cachexia and body weight loss (13).
Most ACCs are sporadic, but some inherited disorders are associated with a high incidence of ACC, such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syn- drome (BWS), Lynch syndrome (LS) and multiple endocrine neoplasia syndrome type 1 (MEN1) (14) (Table 1). LFS is a cancer predisposition syndrome usually caused by an inherited TP53 gene mutation and is characterized by a high occurrence of sarcomas, early onset breast cancer, brain cancer and leukemia (15). ACC accounts for approximately 3% to 10% of LFS-associated cancers (5).
Somatic TP53 mutations have been identified in 25-35% of sporadic ACCs. Nevertheless, these mutations represent a late event during carcinogenesis and have been associated with larger tumors and more advanced disease (14). Somatic mutations in the TP53 gene are a predictor of poor overall survival in adults with ACC (16).
The overexpression of IGF2 is one of the most important mechanisms of adrenocortical tumorigenesis. IGF2 is a potent in vitro growth promoter of adrenal cortex carcinoma cell lines (17). The IGF2 gene is located on chromosome 11p15 and encodes a growth factor that is expressed only through the inherited paternal allele, while the maternal allele is silenced. Genetic or epigenetic alterations in the 11p15 region may alter the expression of the CDKN1C, IGF2 and H19 genes, which are structurally organized in a cluster, increasing IGF2 expression
and inactivating the CDKN1C and H19 genes, which are a negative cell cycle regulator and a transcriptional repressor of IGF2, respectively. BWS is an example of epigenetic alterations in the 11p15 region (18). Macrosomia, macroglossia, viscer- omegaly, neonatal hypoglycemia, and ear and abdominal wall abnormalities characterize BWS. Children with BWS also have a high risk of developing Wilms’ tumors, hepatoblastomas, rhabdomyosarcomas, and ACCs (19).
The gene expression profiles of 94 ACCs in adults demon- strated that the DGL7 and PINK1 genes were differentially expressed between recurrent and nonrecurrent tumors (20). Furthermore, the difference between BUB1B and PINK1 gene expression was a significant predictor of OS in adults. The prognostic importance of the combined expression of these genes was subsequently validated in adult ACC patients from our institution but not in pediatric patients (21).
Diagnostic evaluation
Autonomous cortisol secretion may be identified in almost 70% of patients with ACC, although this finding is clinically unapparent in many patients (22). The European Network for the Study of Adrenal Tumors (e-mail: ENS@T) has sug- gested a comprehensive hormone investigation for cortisol oversecretion (1 mg dexamethasone supression test at 23 h), basal cortisol and ACTH levels, and free 24-h urinary cortisol concentrations), excess of sexual steroid and steroid pre- cursors [DHEA-S, 17-OH-progesterone, androstenedione, testosterone and 17-B-estradiol levels (only in men and postmenopausal women)], primary aldosteronism (aldoster- one and renin levels in patients with hypertension and/or hypokalemia) and pheochromocytoma (total 24-h urinary metanephrine or plasma free metanephrine concentrations) (23). In our center, 11-deoxycortisol levels are also evaluated in patients with masses suspicious for malignancy due to the prognostic value of this parameter.
Most ACCs are large, heterogeneous lesions with irregular contrast uptake (Table 2). On CT, ACC is characterized by a precontrast density greater than 10 Hounsfield units (HU), indicating low lipid content, and absolute contrast wash- out <40% to 50% (1). In fact, malignant primary adrenal lesions usually have a precontrast density >30 HU. Magnetic resonance imaging (MRI) with gadolinium has the same accuracy as CT but may be superior for evaluating vascular invasions. Positron emission tomography (PET) using 18F- fluorodeoxyglucose (FDG) coupled to a CT scan is helpful for
| Syndrome* | Gene mutation | General population prevalence | Prevalence in ACC patients | Other characteristics |
|---|---|---|---|---|
| LFS | TP53 | 1:20.000 | 3-7% (adults) 50-80% (children) | Sarcomas, choroid plexus tumors, cerebral tumors, breast cancer, leukemia, lymphoma. |
| MEN1 | MEN1 | 1:30 000 | 1-2% (adults) | Neuroendocrine tumors, pituitary tumors, parathyroid hyperplasia, adrenal adenomas, angiofibromas. |
| Lynch | MSH2, MSH6, MLH1, PMS2 | 1:440 | 3% (adults) | Colorectal cancer, endometrial cancer, ovarian cancer, pancreatic cancer, brain tumors. |
| BWS | IGF2, CDKN1C | 1:13.000 | Very rare (children) | Wilms' tumors, hepatoblastomas, adrenal adenomas, macrosomia, macroglossia, omphaloceles. |
| FAP | APC | 1:30.000 | <1% | Colonic polyposis, colorectal cancer, desmoid tumors, thyroid cancer, adrenal adenomas, congenital retinal hyperplasia, epidermoid cysts. |
| NF1 | NF1 | 1:3.000 | <1% | Pheochromocytomas, café-au-lait spots, neurofibromas, optic gliomas, Lisch nodules, skeletal abnormalities. |
* LFS: Li-Fraumeni syndrome, MEN1: Multiple endocrine neoplasia type 1, BWS: Beckwith-Wiedemann syndrome, FAP: Familial adenomatous polyposis, NF1: Neurofibromatosis type 1.
Table 2 - Imaging characteristics of the most prevalent tumoral lesions in the adrenal gland (23).
Adrenal Adenoma
Frequently <4 cm, homogeneous and well-defined in shape
CT: density <10 HU* without contrast; 40 to 50% washout or density
<35 HU 10-15 min after contrast injection
MRI: homogenously isointense or hypointense on T2-weighted sequences. Adrenal Carcinoma
Frequently >6 cm, heterogeneous and irregularly shaped.
CT: density > 10 HU without contrast; less than 40 to 50% washout or density
>35 HU 10-15 min after contrast injection
MRI: hyperintense on T2-weighted sequences; < 30% loss of signal intensity on out-of-phase images.
Metastasis
Heterogeneous lesions, frequently affecting both glands, with contrast enhancement.
CT and MRI: similar findings to adrenal carcinomas Pheochromocytoma
Heterogeneous and dense lesions with intense contrast enhancement. MRI: hyperintense on T2-weighted sequences; < 30% loss of signal intensity on out-of-phase images. Myelolipoma
CT: Import lipid content with very low density
MRI: similar behavior as lipid content in the subcutaneous tissues and retroperitoneum on phase-sequences.
* Hounsfield unit.
evaluating adrenal tumors. Malignant lesions have high metabolic activity leading to high FDG uptake. Adrenal adenomas usually have low FDG uptake. However, phe- ochromocytomas, adrenal metastases and rarely adenomas (especially those with high hormonal activity) can have high metabolic activity, resulting in false positives (1).
A careful histopathological evaluation is critical for the correct diagnosis of adrenal tumors, especially for neoplasms localized to the adrenal gland (24). The first step of the analysis consists of evaluating several macroscopic para- meters, including tumor size and weight, capsule integrity, and the presence of hemorrhage or necrosis. The second step is to analyze several microscopic aspects that, together, confirm the diagnosis (25). The Weiss score comprises nine histopathological parameters: three are related to tumor structure (presence of necrosis, diffuse architecture and per- centage of clear cells), three are related to cellular structure (atypical mitoses, number of mitoses and high nuclear grade (Fuhrman 3-4)), and three are related to invasion (vascu- lar invasion, sinusoidal invasion and capsular invasion). According to the Weiss system, a tumor of the adrenal cortex is defined as carcinoma when it presents with at least three of these criteria (26).
Ki67 is a protein expressed in all cell cycle phases except GO and represents a validated cell proliferation index. Ki67 is an important prognostic factor for localized ACCs. When evaluated by immunohistochemistry, a Ki67 index > 10% can differentiate tumors with a high risk of recurrence that are potentially candidates for adjuvant therapy. High levels of Ki67 have also been associated with worse OS in patients with advanced disease and can help in decision-making regarding treatment (27).
Staging
The staging system proposed by the e-mail: ENS@T is the best available system, as this system clearly identifies patient prognosis (22). The e-mail: ENS@T system classifies tumors as stage I or II when they are restricted to the gland and <5 cm or >5 cm in size, respectively. Stage III is deter- mined by adjacent tissue invasion, neoplastic thrombus to the vena cava or renal vein, or regional lymph node metastasis. In addition, stage IV is determined by the presence of distant metastasis.
In 2015, the e-mail: ENS@T proposed that metastatic ACC should be classified into three subgroups (IVa, IVb and IVc). Subgroup IVa included patients with regional lymph node involvement and patients with one or 2 metastatic organs, including lymph nodes. Subgroups IVb and IVc included patients with 3 or more metastatic organs, respectively. Furthermore, some factors associated with worse prognoses are represented in the GRAS score (Grade: Weiss >6 and/or Ki67 >20%; R status: uncomplete resection of the primary tumor; Age: age greater than or equal to 50 years; and Symptoms: symptoms related to the tumor or hormonal production). The combination of the e-mail: ENS@T classifi- cation system and the GRAS score have a good correlation with patient prognosis in stage III and IV adrenal carcinomas (28).
Staging is the most important prognostic factor for ACC patients. There is still considerable variability among pub- lished studies about the likelihood of recurrence and survival. In recent studies, patients with stage I disease had an estimated 5-year OS rate of 66% to 82%. In patients with stage II and III disease, the 5-year OS rate varied from 58% to 64% and 24% to 50%, respectively. In patients with stage IV disease, the estimate 5-year OS rate decreased significantly to 0% to 17%. Other predictors of poor prognosis are older age at diagnosis, mixed syndrome (cortisol and androgen produc- tion) or estrogen-producing ACC, and incomplete resection, either with gross (R2) or microscopic residual disease (R1) (28).
Treatment
Complete surgical resection is the most effective treatment (2). Unfortunately, complete resection is achievable only for locally restricted disease (stages I, II and some stage III tumors) (29). Biopsy of adrenal masses is indicated to confirm the anatomopathological diagnosis of noncortical adrenal lesions or if surgery is not the initial approach, but the anatomopathological diagnosis is necessary before initiating systemic therapy for advanced metastatic disease.
Experienced surgeons should perform surgery with cura- tive intent to avoid incomplete resections and/or rupture of the tumor capsule. A laparoscopic approach is indicated for tumors <6 cm in size without signs of local invasion and should only be performed in highly experienced centers. En bloc resection is recommended when there is adjacent tissue invasion (29). The presence of a vena cava thrombus is
compatible with complete resection, but extracorporeal circulation might be necessary. Prophylactic lymphadenect- omy is not clearly associated with better prognosis and is not mandatory (29).
Patients with a suspected adrenal mass and abnormal glucocorticoid secretion, whether clinical or subclinical, should receive exogenous glucocorticoid replacement dur- ing the perioperative and postoperative periods to prevent acute adrenal insufficiency after resection of the tumor. We recommend that 100 mg of intravenous (i.v) hydrocortisone be administered at the time of anesthetic induction followed by 50 mg of i.v hydrocortisone every 8 h for approximately 2 days, after which hydrocortisone replacement can be provided by oral therapy.
After a complete surgical resection, patients should be followed up every 3 months. The follow-up of these patients should include a complete physical examination, hormonal evaluation and complete radiological evaluation including CT of the thorax and abdomen. After 2-3 years of follow-up without recurrence, imaging studies can be performed every 6 months (22).
Unfortunately, a large number of patients still experience disease recurrence even after complete surgical resection. Adjuvant mitotane treatment is associated with increased disease-free survival but not OS (30). There are discussions regarding how long mitotane should be used in this setting, but most specialists agree that 2 years should be the minimum period. However, mitotane is toxic, and many patients do not tolerate treatment for long periods. Thus, adjuvant mitotane should be considered mainly for high-risk patients (stage III disease or tumors >8-10 cm in size, those with high mitotic rates or a proliferative index Ki67 >10%, and those with microscopic evidence of vascular or capsular invasion). The benefit of mitotane in the low/intermediate- risk group of patients is currently being evaluated in the multicentric, prospective, phase III ADIUVO trial (2). Adjuvant radiation therapy of the adrenal bed is associated with a reduction in local disease recurrence only, with no benefits in OS (31). Few retrospective studies have shown that radiation therapy may improve local control after surgical resection in patients with localized ACCs (31-34). Therefore, the indications for adjuvant radiation therapy are still being debated.
Mitotane is the only available adrenolytic drug for ACC treatment. In addition to its use in the adjuvant setting, mitotane is associated with a 30% objective response rate among patients with metastatic disease in retrospective studies. Mitotane inhibits steroidogenesis and controls hor- mone excess syndromes. Treatment should be initiated at a dose of 1.5 g/d, with a progressive increase up to 5-6 g/d. The goal during treatment is to achieve plasma mitotane levels between 14 and 20 mcg/mL (35). Plasma mitotane concentrations greater than 20 mcg/mL are associated with significant toxicity, including neurological effects (lethargy, somnolence, ataxia, and polyneuropathy, among others). Plasma concentration monitoring should be performed every 4 to 6 weeks during the initiation of treatment. Most patients require at least 2 to 3 months of treatment to achieve thera- peutic levels (35).
The most common side effects of mitotane are gastro- intestinal and are characterized by anorexia, nausea, vomiting, diarrhea and abdominal discomfort. Mitotane also increases the concentrations of cortisol-binding globulin hormone (CBG), steroid-binding globulin (SHBG), and thyroxine-binding
globulin (TBG). Furthermore, mitotane may impair pitui- tary gland function by reducing TSH secretion with consequent hypothyroidism and gonadal function causing hypergonadotropic hypogonadism (23). Cholesterol and triglyceride levels should be monitored regularly due to increases in LDL-cholesterol, HDL-cholesterol and trigly- cerides (35). In the presence of persistently elevated lipid concentrations, statin use is indicated. Statins that are not metabolized by CYP3A4 are preferable, such as rosuvas- tatin and pravastatin.
Notably, mitotane induces adrenal insufficiency due to the inhibition of steroidogenesis enzymes. As mitotane also increases peripheral cortisol metabolism and increases CBG concentrations, patients on glucocorticoid replacement ther- apy need higher replacement doses. The indications for mineralocorticoid replacement depend on potassium and renin levels (35).
Chemotherapy has been used but with limited results. Recently, the first randomized phase III trial with metastatic ACC patients compared to two promising protocols (etopo- side, doxorubicin, cisplatin and mitotane [EDPM] vs. streptozotocin and mitotane) (36). EDPM proved to be superior in terms of the objective response rate (20.5% vs. 7.9%) and progression-free survival (5 m vs. 2.1 m) but was not superior in terms of OS. This study established EDPM as the most evidence-based first-line therapy but also highlighted the necessity for better therapies to be devel- oped for ACC patients (36). A phase I study of imatinib, dacarbazine, and capecitabine included 6 patients with adrenal cancer (37). Among ACC patients, one of the 6 patients presented a partial response with a progression-free survival of 8.8 months (37).
Several phase II studies have investigated molecular target therapies in patients with advanced ACC: inhibitors of epi- dermal growth factor receptor (EGFR; erlotinib and gefiti- nib), mammalian target of rapamycin (mTOR; everolimus), platelet-derived growth factor receptor (PDGFR) and c-KIT (imatinib), and vascular endothelial growth factor (VEGF; bevacizumab) and antibodies against insulin-like growth factor 1 receptor (IGF-1R; figitumumab and cixutumumab) did not demonstrate any effectiveness (38). Linsitinib, an oral IGF-1R inhibitor, was evaluated in a randomized placebo- controlled phase III study including 139 patients with advanced ACC (39). Unfortunately, linsitinib did not improve progression-free survival or OS when compared to placebo.
Surgical debulking can be considered in patients with nonresectable tumor masses, limited sites of metastasis or clinical findings of extreme hormonal excess that prove to be refractory to clinical treatment. Although not completely proven, surgical debulking might offer survival advantages for patients with metastatic disease (29).
Malignant pheochromocytoma and paraganglioma
Pheochromocytomas and paragangliomas (PPGLs) are neuroendocrine tumors derived from chromaffin cells of the adrenal medulla (called pheochromocytomas) or from the sympathetic or parasympathetic autonomic ganglia (paragangliomas). Approximately 80 to 85% of chromaffin- cell tumors are pheochromocytomas, whereas 15 to 20% are paragangliomas. In this review, pheochromocytomas and paragangliomas are referred to as PPGLs. These tumors account for up to 0.6% of cases of adult hypertension and 1% of cases of pediatric hypertension (6). More than 30% of
patients with PPGLs have a hereditary predisposition, and up to 50% of patients with metastatic disease have hereditary germline mutations. To date, at least 14 tumor susceptibility genes have been described (6,40,41). These susceptibility genes can be divided into two clusters: cluster 1 tumors include those with mutations of genes encoding the von Hippel-Lindau (VHL) suppressor, the four subunits of the succinate dehydrogenase complex (SDHA, SDHB, SDHC, and SDHD), and less commonly, the enzyme responsible for flavination of the SDHA subunit (SDHAF2), fumarate hydratase, malate dehydrogenase 2, and prolyl hydroxy- lases 1 and 2. These genetic alterations result in stabilization of hypoxia-inducible factors and activation of the hypoxia signaling pathways. Cluster 2 includes tumors with mutations of the neurofibromatosis type 1 (NF1) tumor suppressor gene, the rearranged during transfection (RET) proto-oncogene, genes encoding transmembrane protein 127 (TMEM127) and MYC-associated factor X (MAX) (6,40,41) (Table 3). We recom- mend genetic screening for PPGL patients in the following situations: those with bilateral pheochromocytomas, all patients with paragangliomas, those with malignant PPGLs and patients younger than 45 years with isolated pheochro- mocytomas (6,42).
Diagnosis of malignant PPGLs
The early diagnosis of PPGLs is crucial for several reasons. Most PPGLs hypersecrete catecholamines and are associa- ted with increased cardiovascular morbidity and mortality. Additionally, PPGLs may cause mass-effect symptoms and have malignant potential. Additionally, familial counseling may result in earlier diagnosis and treatment of asympto- matic carriers. Malignancy is defined by metastases in non- chromaffin tissue. Malignancy in PPGLs affects between 10 and 17% of patients, but the prevalence of such malignancy depends mostly on the germline mutation underlying PPGL pathogenesis (6). Approximately 35% of patients present with synchronous metastases, whereas 65% of patients develop metachronous metastases at a median of 5.5 years after diagnosis (43). Patients who are young and those with larger tumors (>6 cm), positive genetic testing (especially SDHB) or paragangliomas have an increased risk of metastasis and require long-term follow-up. Patients with negative genetic testing and pheochromocytomas <4 cm in size have a lower risk of malignancy (44). In a recent study, 76% of patients with malignant PPGLs had germline mutations in suscept- ibility genes for PPGL (SDHB, 44%; SDHD, 8%; VHL, 12%; NF1, 12%; and RET, 0%) (44). TMEM127 and MAX muta- tions have also been described in patients with malignant PPGLs (45).
| Genes | Frequency (%) | Risk of malignancy in mutation carriers (%) |
|---|---|---|
| Cluster 1 | ||
| VHL | 10 | 6 |
| SDHB | 17 | 69 |
| SDHD | 11 | 31 |
| SDHC | 1 | 17 |
| Cluster 2 | ||
| RET | 9 | 4 |
| NF1 | 4 | 5 |
Biochemical investigation of PPGL patients should include measurement of plasma free metanephrine or 24-h urinary fractionated metanephrine concentrations using liquid chro- matography with mass spectrometry. Total 24-h urinary catecholamine concentrations should also be measured to avoid missing isolated dopamine-producing PPGLs. To measure plasma metanephrines, blood should be drawn with the patient in the supine position. Topographical investigation for PPGLs should be performed only after the biochemical diagnosis of PPGLs. Imaging studies should be initiated with abdominal CT or MRI (6).
The sensitivity of 123 I-metaiodobenzylguanidine (MIBG) scintigraphy is approximately 80% for pheochromocytomas and 50% for paragangliomas (46,47). 123 I-MIBG is recom- mended in patients with an increased risk for metastatic disease due to the large size of the primary tumor, positive genetic testing or extra-adrenal, multifocal or recurrent disease (6). For high-risk patients, we also recommend chest CT to identify lung metastasis. Recent studies have demon- strated that 123I-MIBG SPECT is similar to PET-CT using 18F-FDG to detect PPGLs (48). 123I-MIBG is inferior to 18F-FDG-PET or somatostatin receptor imaging for paragan- gliomas or metastatic disease associated with SDHx-related tumors (49).
Treatment
All patients with a hormonally functional PPGLs should be treated with a-adrenergic receptor blockers to prevent perioperative cardiovascular complications. Preoperative medical treatment for PPGL patients should be initiated at least 14 days before surgery to allow adequate time to normalize blood pressure and heart rate. Since PPGL patients have severe vasoconstriction with volume depletion, treat- ment should include a high-sodium diet and fluid intake to prevent severe hypotension after tumor removal (6). Selective Œ1-receptor blockers (extended-release prazosin or doxazo- sin) to control blood pressure and adrenergic symptoms are recommended. The dose should be started at 1 mg twice daily and titrated to 10-14 mg/d. Preoperative ß-adrenergic receptor blockers are indicated to control tachycardia after the administration of a-adrenergic receptor blockers. The use of ß-adrenergic receptor blockers should not be initiated before a-adrenoceptor blockers because the unopposed stimulation of a-adrenergic receptors can induce adrenergic crises. If the patient has been a-blocked and remains hypertensive, calcium blocker channels should be added. The treatment goal is a blood pressure of less than 130/80 mmHg while seated and greater than 90 mmHg systolic while standing. Furthermore, a-receptor blockers should be discontinued 12h before surgery to prevent refractory hypotension after tumor removal. We recom- mend a-blockade even in normotensive patients if the PPGL is biochemically active.
The treatment of choice for localized PPGLs is laparoscopic resection. Open resection is indicated for tumors >6 cm in size or invasive PPGLs to ensure complete tumor resection, prevent tumor rupture, and avoid local recurrence. Patients with pheochromocytomas larger than 6 cm or paraganglio- mas of any size and/or those who are carriers of SDHB mutations need imaging studies to localize metastatic disease (50). For high-risk patients, we recommend abdominal and pelvic MRI and chest CT every 4-6 months during the first 2-3 years and then annually. Ideally, a whole-body scan, such
| Treatment | Study | n | Objective response rate (%) | Reference |
|---|---|---|---|---|
| 131I-MIBG | Phase II | 50 | 22 | (52) |
| 90Y-DOTATOC | Phase II | 25 | 8 | (53) |
| 177 Lu-DOTATOC | Phase II | 12 | 17 | (54) |
| Cyclophosphamide and dacarbazine* | Retrospective | 52 | 25 | (55) |
| Cyclophosphamide, vincristine and dacarbazine | Retrospective | 17 | 47 | (56) |
| Temozolomide | Retrospective | 15 | 33 | (57) |
| Everolimus | Phase II | 7 | 0 | (59) |
| Sunitinib | Retrospective | 17 | 18 | (60) |
* Optional use of vincristine or doxorubicin.
as an 18F-FDG-PET scan, should be performed for patients with SDHB-positive tumors every 1 or 2 years in addition to routine imaging evaluations.
In a recent retrospective study from the Mayo Clinic, the median overall and disease-specific survivals for malignant PPGLs were 25 and 34 years, respectively. These findings indicate a slow disease course in a subgroup of patients. Shorter survival was correlated with male sex, older age at diagnosis, synchronous metastases, larger primary tumor size, elevated dopamine levels and not undergoing primary tumor resection (43). Patients with metastatic disease and biochemically active tumors should remain «-blocked during the follow-up period. Approximately 70% of patients with malignant PPGLs develop bone metastases (mainly lytic). In all patients with bone metastases, the use of antiresorptive drugs (zoledronic acid every 6 months) may be considered to avoid skeletal-related events (51). Locoregional guided ther- apy, such as surgery and interventional radiology, may be indicated to control pain and prevent fractures and spinal cord compression.
Since the long-term survival is more than 10 years in a subgroup of patients, and systemic therapies have substan- tial toxicity, the initiation of systemic therapy for malignant PPGL patients is justified mainly by tumor progression as defined by RECIST (www.recist.com) (Table 4). The most studied targeted therapy for malignant PPGLs is 131-I-MIBG therapy. Because the structure of MIBG is similar to that of noradrenaline, this isotope can be taken up by tumor cells and cause radiation-induced cell death. Approximately 50% of patients with metastatic lesions have a positive MIBG uptake. Therefore, 131I-MIBG therapy is the first-line therapy for this subgroup of patients. MIBG therapy is associated with response rates ranging from 22 to 48% (50). A single phase II trial included 50 patients with malignant PPGLs who were treated with 131I-MIBG doses ranging from 492 to 1,160 mCi (52). The objective response rate was 22%. Disease progression was found in 35% of patients after a year of follow-up. The estimated 5-year OS rate was 64%. Toxicities included grade 3 to 4 neutropenia (87%) and thrombocyto- penia (83%). Two small studies of 90Y-DOTATOC and 177 Lu- DOTATOC showed tumor response rates of 8% and 17%, respectively (53,54).
A retrospective study from the MD Anderson Cancer Center reported an objective response rate of 25% using cyclophosphamide and dacarbazine and the optional use of vincristine or doxorubicin in 52 patients with malignant PPGLs (55). In addition, a Japanese study reported a partial or minimal tumor response in 8 (47%) out of the 17 patients with malignant PPGLs treated with cyclophosphamide, vincristine and dacarbazine (56). Temozolomide led to a response rate of 33% in patients with malignant PPGLs (57).
Regarding molecular target therapy, patients with malignant PPGLs treated with everolimus had no response (58,59). Sunitinib promoted an objective response in 3 (18%) out of 17 malignant PPGL patients, although 43% of the patients had improvement in blood pressure control. In this study, most of the patients who exhibited a positive response to sunitinib therapy had SDHB germline mutations (60).
Final remarks
Surgery is the only therapy that offers a cure for both ACCs and PPGLs. High-risk ACC and PPGL patients should be carefully monitored for recurrence. Among PPGL patients, SDHB and SDHD mutation carriers have a significant risk of recurrence. Since current treatments for both metastatic ACCs and PPGLs are not associated with a good objective response rate, trials of adjuvant therapies for high-risk patients might be the most promising strategies to decrease recurrence and improve OS. In addition, advanced metastatic ACCs and PPGLs should be preferably addressed in prospective clinical trials testing new molecular target agents.
AUTHOR CONTRIBUTIONS
Almeida MQ and Fragoso MC wrote the manuscript. Latronico AC, Mendonça BB and Bezerra-Neto JE reviewed the manuscript and provided critical feedback about this manuscript.
REFERENCES
1. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocri- nology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2): G1-34, http://dx.doi.org/10.1530/EJE-16-0467.
2. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(12):4551-64, http://dx.doi.org/10.1210/ jc.2013-3020.
3. Latronico AC, Chrousos GP. Extensive personal experience: adrenocor- tical tumors. J Clin Endocrinol Metab. 1997;82(5):1317-24.
4. Faria AM, Almeida MQ. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol Cell Endocrinol. 2012;351(1):52-7, http://dx.doi.org/10.1016/j.mce.2011.09.040.
5. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282-326, http://dx.doi. org/10.1210/er.2013-1029.
6. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Endocrine Society. Pheochromocytoma and para- ganglioma: an endocrine society clinical practice guideline. J Clin Endo- crinol Metab. 2014;99(6):1915-42, http://dx.doi.org/10.1210/jc.2014-1498.
7. Young JL Jr, Miller RW. Incidence of malignant tumors in U. S. children. J Pediatr. 1975;86(2):254-8, http://dx.doi.org/10.1016/S0022-3476(75) 80484-7.
8. Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015;3:45, http://dx.doi.org/10.3389/ fcell.2015.00045.
9. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, et al. An inherited mutation outside the highly conserved DNA- binding domain of the p53 tumor suppressor protein in children and
Adrenal tumors Almeida MQ et al.
adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86(10):4970-3, http://dx.doi.org/10.1210/jcem.86.10.7957.
10. de Sousa GR, Ribeiro TC, Faria AM, Mariani BM, Lerario AM, Zerbini MC, et al. Low DICER1 expression is associated with poor clinical outcome in adrenocortical carcinoma. Oncotarget. 2015;6(26):22724-33, http://dx.doi. org/10.18632/oncotarget.4261.
11. Pinto EM, Billerbeck AE, Villares MC, Domenice S, Mendonça BB, Latronico AC. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol. 2004;48(5):647-50, http://dx.doi.org/ 10.1590/S0004-27302004000500009.
12. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000;88(4):711-36, http://dx.doi.org/ 10.1002/(SICI)1097-0142(20000215)88:4<711:AID-CNCR1>3.0.CO;2-W.
13. Keskin S, Taş F, Vatansever S. Adrenocortical carcinoma: clinicopatho- logical features, prognostic factors and outcome. Urol Int. 2013;90(4):435- 8, http://dx.doi.org/10.1159/000345489.
14. Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist. 2008;13(5):548-61, http://dx.doi.org/10.1634/theoncologist.2007-0243.
15. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48(18):5358-62.
16. Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007; 13(3):844-50, http://dx.doi.org/10.1158/1078-0432.CCR-06-2085.
17. Logié A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y, et al. Auto- crine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol. 1999;23(1):23-32, http://dx.doi. org/10.1677/jme.0.0230023.
18. Leighton PA, Saam JR, Ingram RS, Stewart CL, Tilghman SM. An enhancer deletion affects both H19 and Igf2 expression. Genes Dev. 1995; 9(17):2079-89, http://dx.doi.org/10.1101/gad.9.17.2079.
19. Choufani S, Shuman C, Weksberg R. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet. 2010;154C(3):343-54, http://dx.doi. org/10.1002/ajmg.c.30267.
20. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009;27(7):1108-15, http://dx.doi.org/10.1200/JCO.2008.18.5678.
21. Fragoso MC, Almeida MQ, Mazzuco TL, Mariani BM, Brito LP, Gonçalves TC, et al. Combined expression of BUB1B, DLGAP5, and PINK1 as pre- dictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. Eur J Endocrinol. 2012;166(1):61-7, http://dx.doi.org/10.1530/EJE-11-0806.
22. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, et al. Adrenal cancer: ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol. 2012;23 Suppl 7:vii 131-8, http://dx.doi.org/10.1093/ annonc/mds231.
23. Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collabora- tion with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-46, http://dx.doi.org/10.1530/EJE-18-0608.
24. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989; 13(3):202-6, http://dx.doi.org/10.1097/00000478-198903000-00004.
25. Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26(12):1612-9, http:// dx.doi.org/10.1097/00000478-200212000-00009.
26. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neo- plasms: 25 years later. Hum Pathol. 2009;40(6):757-68, http://dx.doi.org/ 10.1016/j.humpath.2009.03.010.
27. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after com- plete resection. J Clin Endocrinol Metab. 2015;100(3):841-9, http://dx.doi. org/10.1210/jc.2014-3182.
28. Libé R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, et al. ENSAT network. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26(10):2119-25, http://dx.doi.org/10.1093/ annonc/mdv329.
29. Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, et al. German Adrenocortical Carcinoma Study Group. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endo- crinol Metab. 2013;98(1):181-91, http://dx.doi.org/10.1210/jc.2012-2559.
30. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-80, http://dx.doi.org/10.1056/NEJMoa063360.
31. Srougi V, de Bessa J Jr, Tanno FY, Ferreira AM, Hoff AO, Bezerra JE, et al. Adjuvant radiotherapy for the primary treatment of adrenocortical car- cinoma: are we offering the best? Int Braz J Urol. 2017;43(5):841-8, http:// dx.doi.org/10.1590/s1677-5538.ibju.2017.0095.
32. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(11):4501-4, http://dx.doi.org/10.1210/jc.2006-1007.
33. Sabolch A, Else T, Griffith KA, Ben-Josef E, Williams A, Miller BS, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2015;92(2):252-9, http://dx.doi.org/10.1016/j.ijrobp.2015.01.007.
34. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, et al. A retro- spective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):192-7, http://dx.doi.org/10.1210/ jc.2012-2367.
35. Terzolo M, Zaggia B, Allasino B, De Francia S. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2014;21(3):159-65, http://dx.doi.org/10.1097/MED.0000000000000056.
36. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. FIRM-ACT Study Group. Combination chemotherapy in advan- ced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-97, http://dx.doi.org/10.1056/NEJMoa1200966.
37. Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014;14(1):561, http://dx.doi.org/10.1186/1471- 2407-14-561.
38. Hoff AO, Berruti A. 5th International ACC Symposium: Future and cur- rent therapeutic trials in adrenocortical carcinoma. Horm Cancer. 2016; 7(1):29-35, http://dx.doi.org/10.1007/s12672-015-0241-2.
39. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426-35, http://dx.doi.org/10.1016/S1470- 2045(15)70081-1.
40. Currás-Freixes M, Piñeiro-Yañez E, Montero-Conde C, Apellániz-Ruiz M, Calsina B, Mancikova V, et al. PheoSeq: a targeted next-generation sequencing assay for pheochromocytoma and paraganglioma diagnostics. J Mol Diagn. 2017;19(4):575-88, http://dx.doi.org/10.1016/j.jmoldx. 2017.04.009.
41. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181-93, http://dx.doi.org/10.1016/j.ccell.2017.01.001.
42. Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJ, et al. Characteristics of pediatric vs adult pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2017;102(4):1122-32, http://dx. doi.org/10.1210/jc.2016-3829.
43. Hamidi O, Young WF Jr, Iñiguez-Ariza NM, Kittah NE, Gruber L, Bancos C, et al. Malignant Pheochromocytoma and Paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017;102(9):3296-305, http://dx. doi.org/10.1210/jc.2017-00992.
44. Dhir M, Li W, Hogg ME, Bartlett DL, Carty SE, McCoy KL, et al. Clinical Predictors of malignancy in patients with pheochromocytoma and para- ganglioma. Ann Surg Oncol. 2017;24(12):3624-30, http://dx.doi.org/ 10.1245/s10434-017-6074-1.
45. Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al. European- American-Asian Pheochromocytoma-Paraganglioma Registry Study Group. Clinical characterization of the pheochromocytoma and para- ganglioma susceptibility genes SDHA, TMEM127, MAX, and SDHAF2 for gene-informed prevention. JAMA Oncol. 2017;3(9):1204-12, http://dx. doi.org/10.1001/jamaoncol.2017.0223.
46. Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detec- tion of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69(2):181-8, http://dx.doi.org/ 10.1111/j.1365-2265.2008.03256.x .
47. Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9):1448-54, http://dx.doi.org/10.2967/jnumed.108.058701.
48. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700-8, http://dx.doi.org/ 10.1093/jnci/djs188.
49. Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262-9, http://dx.doi.org/10.1200/JCO.2006.09.6297.
Adrenal tumors Almeida MQ et al.
50. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, et al. Therapy of endocrine disease: treatment of malignant pheochro- mocytoma and paraganglioma. Eur J Endocrinol. 2014;171(3):R111-22, http://dx.doi.org/10.1530/EJE-14-0113.
51. Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic para- ganglioma. J Clin Endocrinol Metab. 2013;98(4):1492-7, http://dx.doi. org/10.1210/jc.2012-4231.
52. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162-8, http://dx.doi.org/10.1200/JCO.2008.21.3496.
53. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTA- TOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334-40.
54. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599-606, http://dx.doi.org/ 10.1080/02841860701441848.
55. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, et al. Clinical benefits of systemic chemotherapy for patients with meta- static pheochromocytomas or sympathetic extra-adrenal paragangliomas:
insights from the largest single-institutional experience. Cancer. 2012; 118(11):2804-12, http://dx.doi.org/10.1002/cncr.26577.
56. Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and para- ganglioma. Horm Cancer. 2013;4(2):103-10, http://dx.doi.org/10.1007/ s12672-013-0133-2.
57. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711-20, http://dx.doi.org/10.1002/ijc.28913.
58. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009;41(9):697-702, http://dx.doi.org/10.1055/s-0029-1220687.
59. Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendo- crine tumors or pheochromocytomas/paragangliomas. Cancer. 2012; 118(24):6162-70, http://dx.doi.org/10.1002/cncr.27675.
60. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with pro- gressive metastatic pheochromocytomas and sympathetic paragang- liomas. J Clin Endocrinol Metab. 2012;97(11):4040-50, http://dx.doi.org/ 10.1210/jc.2012-2356.